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Objectives: To evaluate functional outcomes of aripiprazole once-monthly 
(ARI-OM) 400 mg (ARI-OM-400) versus a sub-therapeutic dose of ARI-OM (50 mg; 
ARI-OM-50), oral aripiprazole (ARI), and placebo, in two trials of stable patients with 
schizophrenia. MethOds: Detailed study designs have been reported previously. 
Results are reported for the double-blind, randomized phase of each study. ARI-OM 
is an extended-release injectable suspension given at 400 mg in the gluteal muscle. 
Functional outcome was measured using the Personal and Social Performance scale 
(PSP) and statistically analyzed using analysis of covariance with last observation 
carried forward. Results: A total of 403 patients were randomized to ARI-OM-400 
(n= 269) or placebo (n= 134) in the first (246) trial. PSP scores at endpoint significantly 
worsened with placebo (-6.2) versus ARI-OM-400 (-1.7; p= 0.0002). In the second 
study (247), 662 patients were randomized to: ARI-OM-400 (n= 265); ARI (n= 266); 
or ARI-OM-50 (n= 131). PSP scores with sub-therapeutic ARI-OM-50 significantly 
worsened (-2.39) versus ARI-OM-400 (+0.45; p= 0.03). Similar functional stability 
was observed with ARI (+0.08). cOnclusiOns: Patient functioning, as assessed 
by PSP, was maintained with ARI-OM in both studies but deteriorated in patients 
randomized to either sub-therapeutic doses or placebo, confirming the benefits of 
adequately dosed antipsychotic therapy in preserving functional stability in long-
term management of schizophrenia.
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Objectives: Mild cognitive impairment (MCI) is a state that lies between normal 
cognition and dementia, and the number of cases with the condition is rising as the 
population ages. However, to date, no validated patient reported outcome measure 
(PRO) exists specifically in MCI. We report on a study to develop a PRO for use in 
MCI. MethOds: Semi-structured in-depth interviews were carried out with peo-
ple with MCI in order to determine the questionnaire items. These interviews were 
audio-recorded, transcribed and content analysed. The draft questionnaire was 
refined following feedback from a focus group of patients with a diagnosis of MCI. 
Questionnaires were posted to subjects recruited from memory clinics and research 
databases, the completed questionnaires were analysed using factor analytic tech-
niques to produce the final measure; construct validity was assessed by correlation 
with a generic patient reported outcome measure, the SF-12. Results: Interviews 
were carried out with 23 people with MCI. 280 questionnaires were sent to subjects, 
with a response rate of 56% i.e.146 were included in the analysis. Factor analysis 
produced a 13 item measure tapping two domains of patient reported quality of life 
(‘Emotional Effects’ and ‘Practical Concerns’ ). Internal consistency reliability was high 
for both domains (alpha was 0.91 and 0.85 respectively). Both dimensions were found 
to be highly and significantly correlated with the Mental Component Summary score 
of the SF-12. cOnclusiOns: The Mild Cognitive Impairment Questionnaire (MCQ) is 
a short 13 item measure developed specifically to measure patient reported outcomes 
in people with MCI. It was created on the basis of patient report, and has been shown 
to have good psychometric properties. It is likely to prove valuable in the evaluation 
of treatment regimes in this important and growing patient group.
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Objectives: To guide researchers on the best way to score the Center for 
Epidemiologic Studies – Depression scale (CES-D) by comparing competing mod-
els in the literature. MethOds: Radloff (19777), the original CES-D author, first 
provided scoring for four uncorrelated factors of depression: negative affect 
(NA), positive affect (PA), interpersonal (I), and somatic (S). Sheehan et al. (1995) 
validated four correlated factors in the CES-D. However, Radloff and Sheehan 
results may have differed because Radloff ascribed items of failure and fearfulto 
NA whereas Sheehan assigned a value of I. Following Sheehan’s scoring, Cole et 
al. (2004) presumed a hierarchical factor of depressed mood that included all four 
previously identified factors and posited a 10-item short-form of the CES-D. These 
four models were compared using structural equation modeling for parametric 
models with Bollen-Stine bootstraps to control for multivariate nonnormality in 
225 community-residing subjects, structural validity of the models were com-
pared. Results: Fit statistics for the four models were: Radloff comparative fit 
index (CFI) = .790 & root mean square error of approximation (RMEA) = .011; 
Sheehan CFI = .926 & RMSEA = .053, Cole hierarchical CFI = .927 & RMSEA = 
.052; Cole 10-item CFI = .979 & RMSEA = .041 cOnclusiOns: The uncorrelated 
Radloff model was the poorest fit the day. Both Sheehan and Cole 20-item models 
were decently fit to the data and nearly identical to each other in fit. Finally, the 
10-item Cole short-form of the CES-D was the best fit model to the data. Given 
the brevity of this form and strong fit with the theoretical structure postulated 
by Radloff, researchers may want to consider this form of the CES-D for research 
on depressed mood.
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Objectives: Although depression is a significant co-morbid condition in chronic 
illness, little is known about the prevalence or risk factors for depressive symp-
cohorts were matched 1:1 using “nearest neighbor” greedy match propensity score 
method. HRU (inpatient, outpatient, and medications) and costs were compared 
between the two cohorts. Unit costs were identified from German Diagnosis-related 
Group for inpatient, Einheitlicher Bewertungsmassstab doctor fee scale for out-
patient, and Rote Liste®for medication costs. Direct medical costs over the post-
index period were reported in 2011 Euros. Chi-square for categorical variables and 
t-test or Wilcoxon-Mann-Whitney for continuous variables were used to test for 
differences between cohorts (alpha= 0.05). Generalized linear models with nega-
tive binomial (for HRU) and gamma (for cost) distributions were used to address 
residual differences between matched cohorts. Results: Of 4705 eligible patients, 
737 with ATX (mean age= 10.9 years, 20.8% female) were identified and matched 
1:1 with LA-MPH patients (mean age= 11.2 years, 18.6% female). Patients initiating 
ATX had higher HRU and spending per-patient than patients initiating LA-MPH 
over the post-index: 20.9 (SD= 11.5) vs. 15.7 (SD= 9.0) outpatient prescriptions, 10.1 
(SD= 6.3) vs. 8.3 (SD= 5.3) outpatient visits, € 1029 (SD= 574) vs. € 496 (SD= 334) in retail 
pharmacy costs, and € 1,258 (SD= 739) vs. € 684 (SD= 515) in total all-cause costs (all 
p= < .0001). cOnclusiOns: Among children/adolescents with ADHD in Germany, 
ATX initiators consumed significantly more health care resources and were associ-
ated with significantly higher direct medical costs compared with LA-MPH initiators.
MenTal HealTH – Patient-reported outcomes & Patient Preference studies
PMH48
faCTors assoCiaTeD wiTH Poor aDHerenCe in PaTienTs iniTiaTing 
MeDiCaTion for Major DePressive DisorDer: inTeriM resulTs froM a 
ProsPeCTive, longiTuDinal sTuDy
Lenderking W.R.1, Samp J.2, Hanlon J.1, Hsieh R.3, Akhras K.S.2, Revicki D.A.3
1Evidera, Lexington, MA, USA, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, 
3Evidera, Bethesda, MD, USA
Objectives: To examine factors associated with low adherence in Major Depressive 
Disorder (MDD) patients initiating antidepressant medication (ADM) over a 12-week 
period. MethOds: MDD patients initiating an ADM (with no ADM claim in the 6 
months prior) were identified from a large pharmacy benefits manager database. 
Patients completed paper or online assessments including demographics at baseline 
and patient-reported assessments at baseline, Week 4 and Week 12. Participants were 
classified as having low, medium, or high adherence based on the modified Morisky 
Adherence Scale, with the medium and high adherence groups combined for analysis. 
Logistic regression analyses were run to evaluate the association between adherence 
and age, gender, and patient-reported assessments of depression and sexual dysfunc-
tion (SD), weight gain, sleep problems, nausea, and anxiety. Results: Of 2412 patients 
screened, 591 enrolled and completed baseline assessments. Mean age was 40.4 years 
(standard deviation= 12.1), 82.4% were women, and 87.6% were white. There were 483 
who completed Week 4 and 425 who completed Week 12 assessments. At Week 12, 
39.6% were high adherers, 20.6% were medium adherers, and 39.8% were low adher-
ers. Thirty-eight percent of low adherers had actually discontinued ADM. Among dis-
continuers, 40.6% discontinued due to ADM side effects. In logistic regression models, 
low adherence at Week 4 was significantly associated with weight change ≥ 5 pounds 
(OR= 2.10, 95% CI: 1.32–3.35), anxiety (OR= 1.73, 95% CI: 1.06-2.8) and nausea (OR= 2.31, 
95% CI: 1.06–5.02). Age, gender, depression severity, sexual dysfunction, and insomnia 
were not significant in the logistic model. No factors were significantly associated 
with adherence at Week 12. cOnclusiOns: In this real-world study of patients with 
MDD, nearly 40% of patients were low adherers. Weight change, anxiety, and nausea 
were associated with low adherence at Week 4, but not at Week 12.
PMH49
aDHerenCe, swiTCHing, anD DisConTinuaTion During THe 12 weeks 
following anTiDePressanT iniTiaTion in PaTienTs wiTH DePressive 
DisorDer: resulTs of a ProsPeCTive, longiTuDinal sTuDy
Lenderking W.R.1, Samp J.2, Hanlon J.1, Hsieh R.3, Revicki D.A.3, Akhras K.S.2
1Evidera, Lexington, MA, USA, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, 
3Evidera, Bethesda, MD, USA
Objectives: This study examined patterns of adherence, switching, and discontinu-
ation, in major depressive disorder (MDD) patients initiating antidepressant medica-
tion (ADM) therapy. MethOds: Depressed patients recently initiating an ADM were 
identified from a large pharmacy benefits manager database. Eligible patients were 
invited to participate by phone or mail and enrolled patients completed. Results: 
Of 2,412 patients screened, 591 were enrolled. Average age was 40.4 years (standard 
deviation= 12.1), 82.4% of participants were women, and 87.6% were white. At Week 
4 (n= 483), 39.4% were classified as low adherers with 31 (6.4%) patients having 
discontinued ADM for reasons including side effects (n= 14, 45.2%), feeling better 
(n= 5, 16.1%), cost (n= 5, 16.1%), and lack of efficacy (n= 4, 12.9%). There were 27 (5.6%) 
patients who switched by Week 4. Of these, 12 (44.4%) switched due to side effects, 
11 (40.7%) due to lack of efficacy, and 3 (11%) due to cost. By week 12 (n= 425), 33 
additional patients had discontinued ADM citing similar reasons as those at Week 
4. Of 43 patients who reported switching at Week 4 or Week 12, 15 (34.9%) cited side 
effects, 16 (37.2%) cited lack of efficacy, and 4 (9.3%) cited cost. cOnclusiOns: In 
this real-world, 12-week study of MDD patients initiating ADM, adherence to ADM 
was low. Switching and discontinuing ADM were common within the 12-weeks 
period and were primarily attributed to side effects and lack of efficacy.
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